CliffBio

Sumitomo Pharma America

Patent cliffs & loss of exclusivity

Company

LinkedIn URLhttps://www.linkedin.com/company/sumitomo-pharma-america/
Twitter URLhttps://twitter.com/sumitomopharma
Official Websitehttps://www.us.sumitomo-pharma.com/

13 upcoming patent cliffs

DrugIngredientTypeCliff
  1. APTIOMESLICARBAZEPINE ACETATESmall mol.Aug 2032
  2. APTIOMESLICARBAZEPINE ACETATESmall mol.Aug 2032
  3. APTIOMESLICARBAZEPINE ACETATESmall mol.Aug 2032
  4. APTIOMESLICARBAZEPINE ACETATESmall mol.Aug 2032
  5. KYNMOBIAPOMORPHINE HYDROCHLORIDESmall mol.Apr 2036
  6. KYNMOBIAPOMORPHINE HYDROCHLORIDESmall mol.Apr 2036
  7. KYNMOBIAPOMORPHINE HYDROCHLORIDESmall mol.Apr 2036
  8. KYNMOBIAPOMORPHINE HYDROCHLORIDESmall mol.Apr 2036
  9. KYNMOBIAPOMORPHINE HYDROCHLORIDESmall mol.Apr 2036
  10. LONHALA MAGNAIR KITGLYCOPYRROLATESmall mol.Dec 2036
  11. ORGOVYXRELUGOLIXSmall mol.Sep 2037
  12. GEMTESAVIBEGRONSmall mol.Jul 2042
  13. MYFEMBREEESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIXSmall mol.Nov 2042

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.